-
| ISIN | NL0015000LC2 |
|---|---|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Market Cap | 9M |
|---|---|
| PE Ratio | None |
| Beta | 0.51 |
| Target Price | 14 |
| Dividend Yield | None |
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MYNZ using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025